{"": [124, 132, 0, 133, 1277, 0], "Introduction": [1278, 5585, 0], "Immunogenicity analysis": [5595, 6895, 0], "Efficacy of ChAd-SARS-CoV-2-S in the upper respiratory tract": [6896, 8718, 0], "Efficacy of ChAd-SARS-CoV-2-S in the lower respiratory tract": [8719, 11421, 0], "Pathological analysis of lungs from vaccinated RMs": [11422, 12683, 0], "Results": [5586, 12683, 1], "Limitations of the study": [18780, 20354, 0], "Discussion": [12684, 20354, 1], "Key resources table": [20369, 20394, 0], "Lead contact": [20418, 20602, 0], "Materials availability": [20603, 20885, 0], "Data and code availability": [20886, 21054, 0], "Resource availability": [20395, 21054, 1], "Viruses and cells": [21095, 21891, 0], "RM experiments": [21892, 23536, 0], "Experimental model and subject details": [21055, 23536, 1], "Biosafety and ethics": [23553, 24770, 0], "Chimpanzee adenovirus vectors": [24771, 25119, 0], "Neutralization assay": [25120, 25884, 0], "ELISA": [25885, 26909, 0], "Simian Ad neutralization assays": [26910, 27922, 0], "T cell assay": [27923, 28567, 0], "Measurement of viral burden": [28568, 30064, 0], "Histopathology and immunohistochemistry": [30065, 30988, 0], "Method details": [23537, 30988, 1], "Quantification and statistical analysis": [30989, 31244, 0], "STAR\u2605Methods": [20355, 31244, 1]}